Posted by Michael Wonder on 18 Sep 2017
Neos Therapeutics receives U.S. FDA approval of Adzenys ER (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older
15 September 2017 - Neos Therapeutics to launch third medication in ADHD franchise in January 2018.
Neos Therapeutics today announced that the U.S. FDA has approved Adzenys ER (amphetamine) extended-release oral suspension. Neos Therapeutics is the only company to offer both branded amphetamine and methylphenidate products in extended-release dosage forms.
Once commercially available, Adzenys ER oral suspension will be the third Neos extended release product for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The other Neos extended-release products for the treatment of ADHD are Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets.
